プロフィール詳細

プロジェクトを作成

★★★★★

☆☆☆☆☆

★★★★★

☆☆☆☆☆

Dr. Minal J.に依頼

India

Health Economic Modeler & HEOR specialist | Expert in HTA submission | 15 years' experience in HEOR

プロフィール概要

I am a global healthcare professional with expertise in Health Economics and Clinical Outcomes Research. My previous engagement was with Novartis for the past 10 years. A physician by training, I have a rich experience in creating various types of economic models (cost effectiveness/budget impact models) in wide disease areas ranging from cardiovascular, dermatological, neurological, rare diseases and oncology towards supporting HTA submissions across globe including US, European, Latin America, Asian, African and Middle Eastern Markets.

専門分野

• ☆ Biostatistics
• ☆ Statistics
• ☆ Health Data Analysis
• ☆ Public Health
• ☆ Epidemiology
• ☆ Quality of Life Assessment
• ☆ Health Informatics
• ☆ Research Methodology
• ☆ Feasibility Studies
• ☆ Literature Search
• ☆ Medical Writing
• ☆ Medical Content Writing
• ☆ Research Summaries & Abstracts
• ☆ Technical & Scientific Writing
• ☆ Manuscript & Journal Article Writing
• ☆ Literature Review
• ☆ Systematic Literature Review
• ☆ Health Economics
• ☆ Economic Evaluation
• ☆ Management Consulting

サービス

• Writing
• Research
• Consulting
• Data & AI

Writing Medical Writing, Technical Writing

Research Market Research, Feasibility Study, Gap Analysis, Gray Literature Search, Scientific and Technical Research, Systematic Literature Review, Secondary Data Collection

Consulting Business Strategy Consulting, Healthcare Consulting, Scientific and Technical Consulting

Data & AI Predictive Modeling, Statistical Analysis, Data Visualization

職務経験

Team Lead

Novartis Healthcare Private Limited

1月 2021 - 1月 2023

Senior Manager

Novartis Healthcare Private Limited

9月 2018 - 12月 2020

Manager

Novartis Healthcare Private Limited

9月 2015 - 8月 2018

Senior Analyst - Healtheconomics

Novartis Healthcare Private Limited

8月 2013 - 8月 2018

Senior Stroke Research Fellow

University of Rochester Medical Center

6月 2010 - 6月 2013

Departmental Fellow

University of Rochester Medical Center

10月 2009 - 5月 2010

Research trainee

University of Rochester Medical Center

7月 2009 - 10月 2009

学歴

MPH

University of Rochester Medical Centre

1月 2010 - 8月 2012

Medical Degree (MD)

MUHS

8月 2003 - 5月 2009

認定資格

• Certified in Public Health

  National Board of Public Health Examiners

  1月 2024 - 現在

出版物

JOURNAL ARTICLE

Cesarius Wahono, Laniyati Hamijoyo, Hendrawan Y, Rakinaturia L, Mittal N, Khanna P, Jain M, Isbagio H (2023). Secukinumab in Ankylosing Spondylitis Patients: A Cost-per-Responder Analysis from the Indonesian Health System Perspective . PharmacoEconomics - open.

S Moreno, S Walsh, PJ Khanna, M Jain, N Tanova-Yotova (2022). EE186 Assessment of the Cost-Effectiveness of Secukinumab Versus Risankizumab for the Treatment of Adults With Moderate-to-Severe Plaque Psoriasis in the UK . Value in Health.

(2021). Canadian Rheumatology Association Meeting Virtual Congress February 24 – 26, 2021 . The Journal of Rheumatology.

Philip Hampton, Anna Halliday, Aassi M, Subhashini Subramanian, Jain M, Griffiths CEM (2021). Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials . Journal of the European Academy of Dermatology and Venereology : JEADV.

J. Gratacós, J.M. Martínez-Sesmero, M. Jain, A. Yocolly, P. Gunda, C. Blanch (2019). PBI14 COST-EFFECTIVENESS OF SECUKINUMAB VERSUS OTHER BIOLOGICS AND APREMILAST IN THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS: A SPANISH PERSPECTIVE . Value in Health.

Timo Purmonen, Puolakka K, Devarshi Bhattacharyya, Jain M, Martikainen J (2018). Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective . Cost effectiveness and resource allocation : C/E.

Goeree R, Chiva-Razavi S, Gunda P, Jain M, Jugl SM (2018). Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective . Journal of medical economics.

M Jain, TK Nallagangula, S Jawla, N Rai, D Dev, S Weber, N Cook (2015). Heterogeneity in Relative Efficacy Assessments (Rea) across European Hta Bodies: Opportunity for Improving Efficiency and Speed of Access to Patients? . Value in Health.

Damania D, Kung NT, Jain M, Jain AR, Jason Liew, Rajiv Mangla, Koch GE, Sahin B, Miranpuri AS, Holmquist TM, et al. (2015). Factors associated with recurrent stroke and recanalization in patients presenting with isolated symptomatic carotid occlusion . European journal of neurology.

Gallati CP, Jain M, Damania D, Kanthala AR, Jain AR, Koch GE, Kung NT, Wang HZ, Replogle RE, Babak S. Jahromi (2015). 64-detector CT angiography within 24 hours after carotid endarterectomy and correlation with postoperative stroke . Journal of neurosurgery.

M. Jain, S. Bhattacharyya, S. Gupta, V. Sonathi, R. Mahon, H. Malakar, U. Vudumala, P. Gunda, P. Kumar, G. Partha, et al. (2014). How Does Uncertainty Around Costs And Effects Relate To Uncertainty Around Cost-Effectiveness? . Value in Health.

Jain M, Sonathi V, Rathi H, Thomas SK, Mollon P (2014). The Economic Impact Of Cardiovascular Events In Patients Post Myocardial Infarction: Uk Health Care Perspective . Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Minal Jain, Jonathan Jay Stone, Corey Walker, Maxwell Jacobson, Valerie Phillips, Howard J. Silberstein (2014). 112 Shunt Survival Benefit Associated With Complete vs Partial Revision . Neurosurgery.

Minal Jain, Dushyant Damania, Anunaya Jain, Abhijit Kanthala, Latha Stead, Babk Jahromi (2014). Does Prolonged Length of Stay in the Emergency Department Affect Outcome for Stroke Patients? . Western Journal of Emergency Medicine.

Minal Jain, Kate C. Young, Anunaya Jain, Robert E. Replogle, Curtis G. Benesch, Babak S. Jahromi (2011). Evidence-based treatment of carotid artery stenosis . Neurosurgical Focus.